Out now in International Biopharmaceutical Industry, Optibrium’s CEO, Dr Matt Segall introduces the concept of augmented intelligence. He explains how to use dynamic learning to generate better compounds for your drug discovery programs.
Matt talks through practical examples of augmented intelligence, demonstrating how combining the experience of skilled medicinal chemists with powerful machine learning (ML) generative chemistry algorithms enables humans and machines to learn from and reinforce one another. This overcomes their individual weaknesses and leads to better drug discovery outcomes.
Introduction
The ability of computers to produce new compound structures using ‘generative chemistry’ algorithms is a hot topic in drug discovery. The field has recently been reinvigorated by new machine learning (ML) algorithms that learn what a drug-like molecule ‘looks like’ and subsequently generate large numbers of chemically meaningful structures.
A key advantage of ML algorithms is that they can explore the chemical space around a lead or series, and are able to generate vastly more compounds than either an individual or a team of experts. In addition, these algorithms can be combined with predictive models of target activities and other compound properties, to identify high-quality chemical suggestions.
ML methods have the ability to learn from much more data than any human expert, enabling the identification of complex patterns and guiding future compound optimisation. The resulting generative chemistry systems can also be applied objectively, thereby challenging human biases to enable a more rigorous exploration of optimisation strategies [1].
About the author
Matt Segall, PhD
CEO, Optibrium
Related content from across the site
7th RSC-BMCS AI in chemistry conference
The Chemical Information & Computer Applications Group (CICAG) and Biological & Medicinal Chemistry Sector (BMCS) of the Royal Society of Chemistry are once again organising a conference to present the current advances in AI and machine learning in Chemistry.
26th North American ISSX and JSSX Meeting
The joint ISSX/JSSX meeting is for researchers looking to gain a deeper understanding of drug metabolism and pharmacokinetics.
Optibrium Appoints James Halle as Chief Commercial Officer
Key appointment brings extensive software commercial experience to drive global growth
